Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts
Larimar stock is down over 50% this year due to anaphylactic reactions in a study, rising expenses, and cautious market ...
Larimar Therapeutics price target lowered to $10 from $13 at Baird
Baird lowered the firm’s price target on Larimar Therapeutics (LRMR) to $10 from $13 and keeps an Outperform rating on the shares. Th efirm ...
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives $20.13 Average Target Price from Brokerages
Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) have earned a consensus rating of “Buy” from the twelve ...
Larimar Therapeutics price target raised to $16 from $15 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Larimar Therapeutics (LRMR) to $16 from $15 and keeps a Buy rating on the shares following ...
Robert W. Baird Lowers Larimar Therapeutics (NASDAQ:LRMR) Price Target to $10.00
Larimar Therapeutics (NASDAQ:LRMR – Free Report) had its price target reduced by Robert W. Baird from $13.00 to $10.00 in a ...
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration ...
Larimar: Q4 Earnings Snapshot
Larimar Therapeutics, Inc. LRMR) on Monday reported a loss of $28.8 million in its fourth quarter.
Benzinga.com12d
Larimar Therapeutics Analyst Ratings and Price Targets | NASDAQ:LRMR | Benzinga
The latest price target for Larimar Therapeutics (NASDAQ:LRMR) was reported by Guggenheim on March 25, 2025. The analyst firm set a price target for $26.00 expecting LRMR to rise to within 12 ...